Compare ArcelorMittal SA (MT) vs Summit Therapeutics Inc (SMMT) Price & Performance

ArcelorMittal (MT) trades at $77.15, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing year-over-year sales growth. Recent news highlights expansion in steel capacity and strategic partnerships, while facing headwinds from weak Chinese demand and geopolitical risks in Ukraine. Cash flow trends show a narrowing net outflow, improving from 2023 levels.

The outlook is cautiously optimistic, supported by analyst consensus and European demand improvements, but risks from industry cyclicality and input cost pressures remain. Investment appeal hinges on execution of growth initiatives and macroeconomic stability in key markets.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.